Hennion & Walsh Asset Management Inc. Has $1.41 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...
Intellia Therapeutics: Buying The Path To Commercialization
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
Why Is Intellia Therapeutics Stock Trading Lower On Friday?
Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...
bovnews2d
What’s Fueling Intellia Therapeutics Inc (NTLA) Stock’s -53.57% Loss Below Its 200-Day SMA?
Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $9.42 which represents a decrease of $-0.29 or -2.99% from the prior close of $9.71. The stock opened at $9.76 and touched a low ...
AdvisorNet Financial Inc Buys 4,950 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
AdvisorNet Financial Inc grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 96.4% during the 4th quarter, HoldingsChannel reports. The fund owned 10,085 shares of the company ...
Intellia cuts 27% of workforce as it eyes commercial launch
Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...
Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo
Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on ...
Intellia Therapeutics: Strategic Initiatives and Clinical Progress Justify Buy Rating
J.P. Morgan analyst Brian Cheng has maintained their bullish stance on NTLA stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Intellia Therapeutics (NTLA) Receives a Buy from Bank of America Securities
In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Intellia Therapeutics (NTLA – Research ...
FierceBiotech10d
Intellia, citing 'challenging market environment,' lays off 27% of staff as it takes ax to pipeline
Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...
Nasdaq6d
13 Analysts Have This To Say About Intellia Therapeutics
Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA) in the last three months. The table below offers a ...